Tostran 2 % Norge - norsk - Statens legemiddelverk

tostran 2 %

kyowa kirin holdings b.v. - testosteron - gel - 2 %

Rectogesic 4 mg/ g Norge - norsk - Statens legemiddelverk

rectogesic 4 mg/ g

kyowa kirin holdings b.v. - glyseryltrinitrat - rektalsalve - 4 mg/ g

Abstral 600 mikrog Norge - norsk - Statens legemiddelverk

abstral 600 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 600 mikrog

Abstral 100 mikrog Norge - norsk - Statens legemiddelverk

abstral 100 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 100 mikrog

Abstral 200 mikrog Norge - norsk - Statens legemiddelverk

abstral 200 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 200 mikrog

Abstral 300 mikrog Norge - norsk - Statens legemiddelverk

abstral 300 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 300 mikrog

Abstral 400 mikrog Norge - norsk - Statens legemiddelverk

abstral 400 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 400 mikrog

Abstral 800 mikrog Norge - norsk - Statens legemiddelverk

abstral 800 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 800 mikrog

Crysvita Den europeiske union - norsk - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Moventig Den europeiske union - norsk - EMA (European Medicines Agency)

moventig

kyowa kirin holdings b.v. - naloksegoloksalat - constipation; opioid-related disorders - perifer opioid reseptor antagonister, legemidler mot forstoppelse - behandlingen av opioid-indusert forstoppelse (oic) hos voksne pasienter som har hatt en utilstrekkelig svar på laxative(s).